California State Board of Pharmacy
2720 Gateway Oaks Drive, Suite 100
Sacramento, CA 95833
Phone: (916) 518-3100 Fax: (916) 574-8618
www.pharmacy.ca.gov

Business and Consumer Services Agency
Department of Consumer Affairs
Gavin Newsom, Governor

To: **Board Members**

Subject: **Executive Officer Report**

---

a. NABP District 6, 7, and 8 Meeting

NABP held its joint District 6, 7, and 8 meeting October 18-20, 2026, in Spokane, Washington. The Board is a member of District 8. As the Board's official delegate to NABP, President Oh represents the Board at the meeting, including during business sessions. Sessions included topics ranging from rural pharmacy practice, emergency response, pharmacy technicians, inspections and AI case law overview. Staff participated as part of a panel discussion on inspections. Given the timing of the release of Board meeting materials, a verbal update on the NABP joint district meeting will be provided during the October Board meeting.

As a reminder, California holds two of the leadership positions for District 8, with Anne Sodergren serving as Chairperson and Seung Oh serving as Treasurer.

Next year, California will host the joint district meeting. The meeting will be October 3-5, 2027, at the Hyatt Regency Orange County. **Attachment 1** includes a copy of the Save the Date notice.

b. Draft Report for Next Sunset Review

On January 6, 2025, the Board submitted its most recent Sunset Oversight Review Report. Following oversight hearings, legislation was passed that extended the operations of the Board until January 1, 2030, and that also made significant changes to Pharmacy Law.

To ensure the Board is well positioned to again partner with the Legislature to remove barriers to access and resolve patient safety issues, staff have prepared the first annual update to various portions of the anticipated survey questions that will be requested by the legislative oversight committees during the Board's next sunset review.

As the work of the Board continues, new issues arise, changes in law occur and operations change, it is anticipated that this draft report will change significantly. Although a deadline has not been provided, it is anticipated that the next sunset report will be due at the end of the 2028 calendar year. It is recommended that members, as part of committee meetings, identify potential new issues to be raised as part of ithe Board's next sunset report.

Attachment 2 includes portions of the questionnaire generally used by the oversight committees. This information will ultimately be included in the Board's next sunset report.

c. Regulations Report

The Board has several regulations in various stages of promulgation. Provided below is the status of the pending regulations.

Note: Regulations being considered by the Board during the meeting are not included below.

1. **California Code of Regulations Section, Title 16, 1707.4, Central Fill Pharmacies**
   Approved by the Board: August 1, 2024
   Current Status: Submitted to Office of Administrative Law on October 13, 2026 for final review.

2. **California Code of Regulations Section, Title 16, 1717.11, Remote Processing**
   Approved by the Board: November 6, 2025
   Current Status: Submitted to Business and Consumer Services Agency for final review on September 4, 2026.

3. **California Code of Regulations Section, Title 16, 1793.5, Pharmacy Technician Application**
   Approved by the Board: November 6, 2025
   Current Status: Board staff are working with DCA to prepare the documents for the regulations package.

4. **California Code of Regulations Section, Title 16, 1711, Quality Assurance**
   Approved by the Board: April 29, 2026
   Current Status: Submitted to DCA for pre-review on July 29, 2026.

5. **California Code of Regulations Section, Title 16, 1713.1, Related to Automated Patient Dispensing System Location**
   Approved by the Board: June 25, 2026
   Current Status: Submitted to DCA for pre-review on September 16, 2025.

6. **California Code of Regulations Section, Title 16, 1707.51, Accessible Prescription Drug Labels**
   Approved by the Board: June 20, 2025
   Current Status: Submitted to DCA Acting Director on August 20, 2026.

7. **California Code of Regulations Sections, Title 16, 1702, 1702.1, 1706.6, 1730, 1730.1, 1730.2, and 1749, Advanced Pharmacist Practitioners**
   Approved by the Board: November 6, 2025
   Current Status: Submitted to DCA Acting Director on July 29, 2026.

8. **California Code of Regulations Section, Title 16, 1710, Hospital Pharmacies Exempt from CAMER**
   Approved by the Board: November 6, 2025

Current Status: Submitted to DCA Acting Director on August 10, 2026.

9. **California Code of Regulations, Title 16, Sections 1793.7 and 1793.8, Requirements for Pharmacies Employing Pharmacy Technicians in Hospitals with Clinical Pharmacy Programs**
   Approved by the Board: November 6, 2025
   Current Status: Submitted to DCA Acting Director on August 12, 2026.

10. **California Code of Regulations Sections, Title 16, Sections 1715, 1715.1, 1746, 1746.1, 1746.2, 1746.3, 1746.4, 1746.5, 1747, and 1784, and Proposed Amendment to Title 16, Sections 1732.5, 1735.1 and 1736.1, Related to Self-Assessments and Standard of Care**
    Approved by the Board: April 29, 2026
    Current Status: Approved by Business and Consumer Services Agency to Notice with the Office of Administrative Law on October 7, 2026. Board staff are preparing documents for Notice on October 23, 2026.

11. **California Code of Regulations Sections, Title 16, Section 1707, Offsite Storage**
    Approved by the Board: June 25, 2026
    Current Status: Board staff are working on drafting rulemaking documents.

12. **California Code of Regulations Sections, Title 16, Section 1708.2. Discontinuance of Business closure and cessation**
    Approved by the Board: June 25, 2026
    Current Status: Board staff are working on drafting rulemaking documents.

d. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss

In September the FDA released information, FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. As part of its release, the FDA shared that it is aware that some patients and health care professionals may look to unapproved versions of GLP-1 drugs, including semaglutide and tirzepatide, as an option for weight loss. FDA noted that this can be risky for patients. The FDA also noted that retatrutide and cagrilintide cannot be used in compounding under federal law.